New blood tests for Alzheimer’s won’t give you an instant diagnosis. Here’s what they’ll tell you instead.
Articles on Alzheimer's disease detection
Displaying all articles
These tests could aid with early detection of the disease or identify at-risk people.
The test could someday help diagnose Alzheimer’s related memory issues without the need for unnecessary waits or time consuming procedures.
Although autosomal dominant Alzheimer’s disease is very rare, studying it provides researchers with valuable information on how the disease progresses in general.
Ruth Itzhaki has spent more than 30 years researching whether certain common viruses play a role in the development of Alzheimer’s. But for years her research was greeted with hostility.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
A neuroscientist and a clinician watched two new films about dementia. They recognised what they saw.
In this new study, people who were overweight had fewer brain cells and lower levels of blood flow compared to people of a normal weight.
Knowing what cells are more vulnerable could some day help researchers know why these cells are more vulnerable than others.
A blood test to detect Alzheimer’s disease in people who have symptoms and even those who don’t has been shown to work. Scientists still need to improve its accuracy rate to almost 100%, however.
Our study found that people who had higher repetitive negative thinking patterns experienced more cognitive decline over a four-year period.
Scientists explain why commercial gene testing should be used with caution.
Alzheimer’s is one of the most dreaded and difficult diseases, and it has been notoriously difficult to diagnose. Could that change in the coming years with the advent of new blood tests?
Alzheimer’s is not only the third leading cause of death in the U.S. but also the most dreaded diagnosis. Genetic testing can help determine susceptibility, but knowing whether to test isn’t easy.
Top contributors
-
Research Fellow in Neuroimmunology, UCL
-
Professor of Pharmacology and Neurology, Director Center for Neurodegenerative Diseases, Emory University
-
Professor of Neurology and Neuroscience, University of Florida
-
Chair Professor, Translational Clinical Neuropsychology, University of Sheffield
-
Associate professor, Royal Holloway, University of London
-
Professor of Biology, Boise State University
-
Senior research fellow, UCL
-
Professor Emeritus of Molecular Neurobiology at the University of Manchester and a Visiting Professorial Fellow, University of Oxford
-
Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
-
Postdoctoral research associate, Cardiff University
-
Lecturer, Neuroscience of Dementia, University of Sheffield
-
Professor of cognitive pharmacology, Université du Québec à Montréal (UQAM)
-
Professor of Dementia Studies & Education, University of Tasmania
-
PhD Candidate in Neurodegeneration & Neuroinflammation, UCL
-
Professor of Genetic Dementia Research, Karolinska Institutet